A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions
- Sponsors INSYS Therapeutics, Inc
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 13 Mar 2018 New trial record